0R15 8539.0 2.1534% 0R1E 8600.0 3.3654% 0M69 None None% 0R2V 190.25 -0.1312% 0QYR 1345.5 2.0871% 0QYP 424.0 0.5931% 0LCV 146.6464 -1.3147% 0RUK None None% 0RYA 1631.0 -0.6094% 0RIH 171.3 0.9131% 0RIH 174.9 2.1016% 0R1O 186.0 9820.0% 0R1O None None% 0QFP None None% 0M2Z 298.3 -0.6495% 0VSO None None% 0R1I None None% 0QZI 474.5 0.6363% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-16T16:44:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 116.04M | 84.14M | 4.64M | 60.23M | -9.92600M |
| Minority interest | 0.00000M | 1.19M | -0.30600M | -2.43400M | -0.92200M |
| Net income | 91.39M | 62.12M | 1.10M | 48.94M | -5.73800M |
| Selling general administrative | 45.06M | 51.43M | 50.38M | 50.28M | 49.89M |
| Selling and marketing expenses | 21.53M | 17.49M | 14.78M | 12.83M | 8.16M |
| Gross profit | 248.86M | 199.74M | 143.34M | 131.92M | 106.98M |
| Reconciled depreciation | 28.74M | 26.75M | 25.18M | 21.12M | 16.52M |
| Ebit | 78.76M | 43.13M | -14.22600M | -21.16000M | -25.13900M |
| Ebitda | 107.50M | 69.89M | 10.95M | -0.03900M | -8.62300M |
| Depreciation and amortization | 28.74M | 26.75M | 25.18M | 21.12M | 16.52M |
| Non operating income net other | 9.21M | 14.93M | -5.94300M | 60.39M | -1.06000M |
| Operating income | 78.76M | 43.13M | -14.22600M | -0.03900M | -8.62300M |
| Other operating expenses | 391.49M | 367.88M | 338.89M | 322.40M | 303.29M |
| Interest expense | 1.85M | 0.89M | 0.37M | 0.12M | 0.24M |
| Tax provision | 23.48M | 20.63M | 3.54M | 13.72M | -3.26600M |
| Interest income | 1.32M | 0.60M | 0.64M | 1.00M | 0.46M |
| Net interest income | -0.52500M | -0.28400M | 0.27M | 0.88M | 0.21M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 23.48M | 20.63M | 3.54M | 13.72M | -3.26600M |
| Total revenue | 498.99M | 437.77M | 349.85M | 322.36M | 294.67M |
| Total operating expenses | 141.36M | 129.85M | 132.39M | 131.96M | 115.61M |
| Cost of revenue | 250.13M | 238.03M | 206.51M | 190.43M | 187.68M |
| Total other income expense net | 37.28M | 41.00M | 18.86M | 60.27M | -1.30300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 91.39M | 63.51M | 1.10M | 46.51M | -6.66000M |
| Net income applicable to common shares | 91.39M | 62.12M | 1.40M | 48.94M | -5.73800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 741.99M | 671.53M | 631.24M | 586.97M | 513.56M |
| Intangible assets | 34.17M | 35.56M | 36.67M | 37.52M | 38.32M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7.56M | 7.27M | 6.78M | 9.54M | 5.49M |
| Total liab | 213.33M | 226.01M | 182.51M | 159.44M | 149.20M |
| Total stockholder equity | 528.66M | 445.52M | 402.31M | 381.37M | 332.44M |
| Deferred long term liab | - | 0.53M | 0.74M | 0.87M | 1.03M |
| Other current liab | 4.57M | 9.08M | 1.08M | 2.04M | 57.28M |
| Common stock | 0.00600M | 0.00600M | 0.00500M | 0.00500M | 0.00500M |
| Capital stock | 0.00600M | 0.00600M | 0.00500M | 0.00500M | 0.00500M |
| Retained earnings | 271.72M | 180.34M | 117.77M | 116.37M | 67.48M |
| Other liab | 21.93M | 22.72M | 18.66M | 13.72M | 10.39M |
| Good will | 3.13M | 3.31M | 3.94M | 3.63M | 3.95M |
| Other assets | 59.38M | 39.06M | 50.88M | 37.03M | 40.54M |
| Cash | 156.10M | 126.35M | 92.64M | 73.69M | 86.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 94.86M | 103.81M | 112.20M | 90.01M | 106.83M |
| Current deferred revenue | - | - | - | - | -56.09500M |
| Net debt | -53.51600M | -21.69000M | -25.37200M | -7.06000M | -36.12400M |
| Short term debt | 6.05M | 5.18M | 15.62M | 10.92M | 18.23M |
| Short long term debt | 3.05M | 2.20M | 12.26M | 7.74M | 18.23M |
| Short long term debt total | 102.58M | 104.66M | 67.27M | 66.62M | 50.21M |
| Other stockholder equity | 265.55M | 271.94M | 288.25M | 269.68M | 268.96M |
| Property plant equipment | 238.27M | 244.24M | 260.06M | 233.86M | 210.42M |
| Total current assets | 378.32M | 318.12M | 279.68M | 255.24M | 220.34M |
| Long term investments | 2.41M | 3.98M | - | - | - |
| Net tangible assets | 491.36M | 406.65M | 361.69M | 340.21M | 290.17M |
| Short term investments | 19.66M | 10.32M | 12.98M | 11.68M | 2.83M |
| Net receivables | 88.97M | 78.93M | 66.39M | 45.69M | 52.21M |
| Long term debt | 72.84M | 74.78M | 34.19M | 39.39M | 31.98M |
| Inventory | 103.58M | 92.81M | 96.83M | 110.50M | 69.32M |
| Accounts payable | 84.24M | 89.55M | 95.50M | 77.05M | 87.42M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 46.42M | 46.16M | 31.92M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8.62400M | -6.76500M | -3.72100M | -4.68700M | -4.01300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.00600M | 0.00600M | 0.00500M | 0.00500M | 0.00500M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 271.72M | 180.34M | 117.77M | 116.37M | 67.48M |
| Treasury stock | -189.52400M | -150.47900M | -121.81200M | -97.62700M | -75.47600M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 20.86M | 16.66M | 5.25M | 11.16M | 9.92M |
| Deferred long term asset charges | - | - | - | - | 30.62M |
| Non current assets total | 363.67M | 353.41M | 351.55M | 331.73M | 293.22M |
| Capital lease obligations | 26.70M | 27.68M | 20.82M | 19.49M | - |
| Long term debt total | 72.84M | 74.78M | 34.19M | 39.39M | 31.98M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -7.79200M | 1.40M | -1.14600M | -8.81500M | -0.21700M |
| Change to liabilities | -0.73600M | 3.02M | 20.61M | -11.72000M | 29.16M |
| Total cashflows from investing activities | -32.77700M | -28.67200M | -36.41500M | -50.52700M | -42.18200M |
| Net borrowings | -2.18800M | 30.36M | -0.88000M | -3.21100M | 3.07M |
| Total cash from financing activities | -26.43900M | -37.01800M | -2.24600M | -3.78300M | 25.01M |
| Change to operating activities | -5.00800M | 0.37M | -5.64600M | -6.21700M | 1.38M |
| Net income | 91.39M | 63.30M | 1.10M | 46.51M | -6.66000M |
| Change in cash | 29.75M | 32.08M | 18.96M | -12.65200M | 20.74M |
| Begin period cash flow | 126.59M | 94.51M | 75.55M | 88.20M | 67.46M |
| End period cash flow | 156.33M | 126.59M | 94.51M | 75.55M | 88.20M |
| Total cash from operating activities | 89.18M | 97.99M | 57.27M | 41.76M | 38.19M |
| Issuance of capital stock | - | - | 0.00000M | 18.30M | 38.04M |
| Depreciation | 28.74M | 26.75M | 25.18M | 21.12M | 16.52M |
| Other cashflows from investing activities | -0.95100M | -2.61200M | -1.41400M | -0.15700M | 4.84M |
| Dividends paid | - | - | - | - | 20.31M |
| Change to inventory | -11.74600M | 1.26M | 15.30M | -41.10300M | -5.98400M |
| Change to account receivables | -10.13200M | -14.92100M | -20.16000M | 6.70M | -16.29500M |
| Sale purchase of stock | -39.90900M | -28.87300M | -24.42500M | -22.29100M | -25.04700M |
| Other cashflows from financing activities | 15.25M | 29.76M | 30.58M | 6.99M | 38.04M |
| Change to netincome | 2.73M | 8.04M | 20.58M | 22.87M | 16.70M |
| Capital expenditures | 24.03M | 27.46M | 33.85M | 41.55M | 46.81M |
| Change receivables | -10.13200M | -14.92100M | -20.16000M | 6.70M | -16.29500M |
| Cash flows other operating | -7.55900M | 13.81M | -1.68000M | 0.40M | 4.76M |
| Exchange rate changes | - | - | - | - | -0.27400M |
| Cash and cash equivalents changes | 29.96M | 32.30M | 18.61M | -12.54800M | 20.74M |
| Change in working capital | -32.17700M | -1.92400M | 9.13M | -51.74700M | 12.10M |
| Stock based compensation | 17.86M | 18.69M | 20.50M | 17.30M | 16.68M |
| Other non cash items | -0.87800M | -13.03100M | 0.24M | 1.04M | 1.43M |
| Free cash flow | 65.15M | 70.54M | 23.41M | 0.21M | -8.61700M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AMPH Amphastar P |
-0.55 1.30% | 41.89 | 24.38 | - | 4.73 | 4.71 | 5.28 | 14.10 |
| ZTS Zoetis Inc |
0.68 0.39% | 173.96 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.51 1.41% | 36.61 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
6.91 3.93% | 182.50 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.045 0.34% | 13.35 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
11570 6th Street, Rancho Cucamonga, CA, United States, 91730
| Name | Title | Year Born |
|---|---|---|
| Dr. Ziping Luo Ph.D. | Chairman, Chief Scientist & COO | 1950 |
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, Pres, CEO, Chief Scientific Officer & Director | 1947 |
| Mr. William J. Peters M.B.A. | CFO, Exec. VP of Fin., Treasurer & Director | 1968 |
| Mr. Jacob Liawatidewi M.B.A. | Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director | 1974 |
| Mr. Rong Zhou M.S. | Exec. VP of Production Center | 1959 |
| Dan Dischner M.B.A. | VP of HR & Corp. Communication | NA |
| Tony Marrs M.B.A., M.P.H. | Sr. VP of Regulatory Affairs & Clinical Operations | NA |
| Mr. Peter Langosh | VP of Operational Improvement and VP of Internal Audit | 1953 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...